Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Pathologic Complete Response × Nivolumab × 30 days × Clear all

Sponsor

Conditions

Melanoma 29 Carcinoma, Non-Small-Cell Lung 21 Carcinoma, Renal Cell 19 Neoplasm Metastasis 12 Lung Neoplasms 11 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Carcinoma, Hepatocellular 8 Adenocarcinoma Of Esophagus 8 Neoplasms 7 Carcinoma, Transitional Cell 7 Urinary Bladder Neoplasms 6 Skin Neoplasms 6 Ovarian Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Merkel Cell 5 Small Cell Lung Carcinoma 4 Glioblastoma 4 Esophageal Neoplasms 4 Breast Neoplasms 4 Brain Neoplasms 4 Uveal Melanoma 3 Urethral Neoplasms 3 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Oropharyngeal Neoplasms 3 Nasopharyngeal Carcinoma 3 Multiple Myeloma 3 Mouth Neoplasms 3 Lymphoma, Non-Hodgkin 3

Interventions

pembrolizumab 2 durvalumab 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Chemoradiotherapy 2 Carboplatin 2 Capecitabine 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 relugolix 1 pexidartinib 1 pertuzumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 enzalutamide 1 dostarlimab 1 cemiplimab 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡